Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) - PubMed (original) (raw)
Clinical Trial
Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)
J Barker et al. Br J Dermatol. 2011 Nov.
Abstract
Background: Infliximab is indicated for treatment of moderate-to-severe plaque psoriasis in adults whose disease cannot be controlled with other systemic therapies, including methotrexate (MTX). To date, no studies have directly compared the efficacy and safety of infliximab and MTX.
Objectives: To compare the efficacy and safety of infliximab vs. MTX in adults with moderate-to-severe plaque psoriasis.
Methods: MTX-naïve patients (n = 868) were randomized 3:1 to receive infliximab 5 mg kg⁻¹ at weeks 0, 2, 6, 14 and 22 or MTX 15 mg weekly with a dose increase to 20 mg weekly at week 6 if the Psoriasis Area and Severity Index (PASI) response was < 25%. At week 16, patients with < PASI 50 response could switch treatment groups. The primary efficacy endpoint was PASI 75 response at week 16. Major secondary efficacy endpoints were PASI 75 response at week 26, and the proportion of patients achieving a Physician's Global Assessment (PGA) score of cleared (0) or minimal (1) at weeks 16 and 26. Others included Dermatology Life Quality Index, 36-Item Short Form Health Survey, and PGA, PASI 50, PASI 75 and PASI 90 responses over time.
Results: The primary endpoint was achieved by a significantly greater proportion of infliximab-treated patients (508/653, 78%) than MTX-treated patients (90/215, 42%; P < 0·001). Key secondary endpoints also were achieved by a greater proportion of infliximab-treated patients. Similar responses were observed at week 26 in patients who switched from MTX to infliximab at week 16. Overall adverse event (AE) incidence was comparable between groups, but incidence of serious and severe AEs was slightly higher in the infliximab group.
Conclusions: Infliximab was well tolerated and more efficacious than MTX in patients with moderate-to-severe plaque psoriasis. Infliximab also was efficacious in patients who failed MTX and switched to infliximab.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists.
Similar articles
- Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H, Nakagawa H; Japanese Infliximab Study investigators. Torii H, et al. J Dermatol Sci. 2010 Jul;59(1):40-9. doi: 10.1016/j.jdermsci.2010.04.014. Epub 2010 May 4. J Dermatol Sci. 2010. PMID: 20547039 Clinical Trial. - Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J. van de Kerkhof PC, et al. Br J Dermatol. 2008 Nov;159(5):1177-85. doi: 10.1111/j.1365-2133.2008.08771.x. Epub 2008 Jul 31. Br J Dermatol. 2008. PMID: 18673365 Clinical Trial. - Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Brimhall AK, et al. Br J Dermatol. 2008 Aug;159(2):274-85. doi: 10.1111/j.1365-2133.2008.08673.x. Epub 2008 Jun 10. Br J Dermatol. 2008. PMID: 18547300 Review. - Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J. Reich K, et al. Curr Med Res Opin. 2008 May;24(5):1237-54. doi: 10.1185/030079908x291985. Epub 2008 Mar 19. Curr Med Res Opin. 2008. PMID: 18355421 Review.
Cited by
- Research trends and hotspots in biologics for plaque psoriasis: A bibliometric study from 2004 to 2023.
Huang S, Duan X, Bai Y. Huang S, et al. Heliyon. 2024 Jul 30;10(15):e35446. doi: 10.1016/j.heliyon.2024.e35446. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170305 Free PMC article. - Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients.
Erduran F, Emre S, Hayran Y, Adışen E, Polat AK, Üstüner P, Öztürkcan S, Öztürk P, Ermertcan AT, Selçuk LB, Aksu EK, Akbaş A, Kalkan G, Demirseren D, Kartal SP, Topkarcı Z, Kılıç A, Yaldız M, Aytekin S, Hızlı P, Gharehdaghi S, Borlu M, Işık L, Botsalı BR, Solak EÖ, Albayrak H, Gönülal M, Balcı DD, Polat M, Daye M, Ataseven A, Yıldız S, Özer İ, Zorlu Ö, Doğan S, Erdemir VA, Dikicier BS. Erduran F, et al. Arch Dermatol Res. 2024 May 25;316(6):278. doi: 10.1007/s00403-024-03066-1. Arch Dermatol Res. 2024. PMID: 38796658 - Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis.
Shellard EM, Rane SS, Eyre S, Warren RB. Shellard EM, et al. Biomolecules. 2024 May 3;14(5):548. doi: 10.3390/biom14050548. Biomolecules. 2024. PMID: 38785955 Free PMC article. Review. - Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis.
Greenzaid J, Feldman S. Greenzaid J, et al. Clin Pharmacokinet. 2024 Feb;63(2):137-153. doi: 10.1007/s40262-023-01341-4. Epub 2024 Jan 27. Clin Pharmacokinet. 2024. PMID: 38280146 Review. - A Systematic Review Evaluating the Effectiveness of Several Biological Therapies for the Treatment of Skin Psoriasis.
Alzahrani SA, Alzamil FM, Aljuhni AM, Al Thaqfan NA, Alqahtani NY, Alwarwari SA, Alkharashi AA, Alzabadin RA, Alzehairi RA, Alhajlah AA. Alzahrani SA, et al. Cureus. 2023 Dec 15;15(12):e50588. doi: 10.7759/cureus.50588. eCollection 2023 Dec. Cureus. 2023. PMID: 38222196 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical